



Freedom of Information request & West Norfolk CCG response

WN-2017-00111 – CGM and FGM

1. Does your Clinical Commissioning Group (CCG) have a policy on the use and funding of continuous glucose monitoring (CGM)?

There is a CGM policy statement which is currently under review. In the meantime, all requests for funding are being channelled via the IFR-Drugs Panel and if they do not meet the criteria within the policy for treatment then clinical exceptionalty needs to be demonstrated.

If yes –

a) What is the scope of the CGM policy?

To qualify for funding all criteria need to be met.

b) Does it specify specific CGM systems? If yes, which ones?

No.

c) Does it differentiate between CGM and FGM (Flash Glucose Monitoring eg Libre)?

Yes, there is a negative policy for the use of FGM.

If no – proceed to question 2.

2. In light of there being no CCG policy on the use and funding of CGM what alternative funding routes exist?

I. Individual funding requests

a) How many IFR applications were received in the last year for CGM?

6

b) How many IFR applications were received in the last year for FGM?

0

II. Funding allocation by the hospital provider

a) How is the funding allocated e.g. quota, fixed funds, etc.?

N/A – see response to Q1.

III. Self-funding

a) Is this through private medical insurance?

N/A – see response to Q1.

IV. Other. Please specify

N/A – see response to Q1.

3. If your CCG currently has no policy in place for CGM is this something that is being considered for development?

a) If yes - are there timelines in place for this?

N/A – see response to Q1.

b) Who is responsible for developing the CGM policy?

N/A – see response to Q1.